Abbott Laboratories Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Margins
| Current | |
|---|---|
| EBITDA Margin | 24.0% |
| Operating Margin | 17.1% |
| Net Margin | 13.9% |
Returns
Balance Sheet Health
Quality Metrics
Multi-Year Trend
Dividend
Capital Allocation
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Medical Devices | $21.4B | +12.7% | View detailsAbbott received key product approvals in 2025, including FDA approval and CE Mark for the Volt Pulsed Field Ablation System, FDA approval of the Tendyne transcatheter mitral valve replacement system, and CE Mark for the TactiFlex Duo Ablation Catheter. |
| Diagnostic Products | $8.9B | -4.3% | View detailsIn November 2025, Abbott announced an agreement to acquire Exact Sciences for approximately $20,600,000,000, which closed on March 23, 2026, raising total diagnostics sales to more than $12,000,000,000 annually. |
| Nutritional Products | $8.5B | +0.5% | View detailsAbbott expects to increase volume growth with the launch of several new products in 2026. |
| Established Pharmaceutical Products | $5.5B | +6.6% | View detailsAbbott plans to focus on expanding its product portfolio in key therapeutic areas and biosimilars in emerging markets. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.